Abstract
Motivation People living with tunnel vision caused by Retinitis pigmentosa (RP) oftentimes face challenges navigating and avoiding obstacles due to a severely decreased Visual Field. Previous studies have shown that gaze training – guided tasks to encourage specific gaze behavior – help improve visual performance in patients with limited Visual Field. We propose a Virtual-Reality based, at-home gaze training – to the best of our knowledge the first of its kind – to increase effective eye movements and navigation performance of RP patients in a real-world obstacle course.
Methods A group of RP patients (n=8) participated in a study consisting of two 4-week-phases, both carried out by the same patient group in randomized order: In the ‘training phase’, participants carried out a Virtual-Reality gaze training for 30 minutes per day; In the ‘control phase’, no training occurred. Before and after each phase, participants were tasked to move through a randomized real-world obstacle course. Navigation performance in the obstacle course as well as eye-tracking data during the trials were evaluated. The study is registered at the German Clinical Trials Register (DRKS) with the ID DRKS00032628.
Results On average, the time required to move through the obstacle course decreased by 17.0% after the training phase (p < 0.001), the number of collisions decreased by 50.0% (p < 0.001) and the average visual area observed by participants increased by 4.41% (p < 0.001). In comparison, after the control phase, the time required to move through the obstacle course was found to have decreased by 5.9% (p = 0.003), collisions decreased by 10.4% (p = 0.609) and the observed visual area increased by 2.06% (p = 0.0835).
Conclusion The performance increase over the training phase significantly surpasses the natural learning effect found in the control phase, suggesting that Virtual-Reality based gaze training can improve real-world navigation performance and effective gaze movements of patients with RP. The training is available as work-in-progress open-source software.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Registry: German Clinical Trials Register (DRKS) ID: DRKS00032628 URL: https://drks.de/search/de/trial/DRKS00032628 The registration was done retrospectively, as the study was originally considered as non-interventional observation study, not as clinical trial. Prompted by later feedback, this decision was reconsidered and the study was registered.
Funding Statement
This work was supported by the Deutsche Forschungsgemeinschaft (DFG), URL: https://www.dfg.de/en/ (Grant: DFG IV 167/5-1 to II). The funder did not play any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Institutional Review Board of the Medical Faculty of the University of Tuebingen gave ethical approval for this work in accordance with the 2013 Helsinki Declaration. The project number is 628/2018BO2. Patients were recruited in the time from June 9, 2022 to November 22, 2022. All participants signed informed consent forms.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Registered at the German Clinical Trials Register (DRKS). DRKS-ID: DRKS00032628
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
